Ignota labs funding news – London-based Ignota Labs Secures €6.6 Million in Seed Funding

The funding will be used to expand the pipeline by acquiring additional distressed assets and for advancement into early-stage clinical trials of their first asset, a PDE9A inhibitor.

Drug safety failures are a leading cause of clinical trial failures, preventing over 56% of drugs from reaching patients and costing the pharmaceutical industry more than $400 billion annually.

Read also - Fund F funding news – Vienna-based Fund F Closes First Fund at €28Million

Ignota Labs addresses this issue by applying deep learning, cheminformatics, and bioinformatics to uncover and resolve the root causes of drug toxicity, unlocking new opportunities for assets that would otherwise be abandoned.

Sam Windsor, CEO and Co-Founder, Ignota Labs said, “We’re thrilled to have the support of this leading investor syndicate in our mission to rescue promising yet struggling drugs with our technology, Traditional safety assessments reveal when something is wrong, but our platform goes a step further by identifying the exact molecular and biological issues to provide actionable insights to re-engineer and revive therapies. With this funding, we can expand our efforts to salvage distressed assets and accelerate the delivery of life-saving therapies to patients.”

Todd Kimmel, Founder and Managing Partner, Montage Ventures said, “Ignota Labs is solving one of the most critical challenges in drug development, rescuing promising therapies that would otherwise be abandoned due to safety issues, Their SAFEPATH platform represents a groundbreaking approach, combining cutting-edge AI with deep scientific expertise to address the root causes of drug toxicity. We believe Ignota Labs has the ability to enable more drugs to make it to the clinic and get to the patients who need them.”

Krish Ramadurai, Partner at AIX Ventures said, “Ignota is redefining drug development and pioneering a new era of predictive and engineerable biology—where AI systematically de-risks therapeutic development by designing safer, more effective drugs with precision, Their approach shifts biopharmaceutical R&D from trial-and-error to a rational, data-driven process, enabling molecules to be precisely refined at scale to accelerate clinical development. I’m incredibly excited about their potential to transform AI-driven drug discovery and unlock massive value from previously failed assets to improve patient outcomes.”

‍About Ignota Labs

Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hope to patients. More than half of all clinical trials fail due to safety issues, resulting in a staggering $400 billion annual loss and delaying life-saving treatments for patients.